BARCELONA, Spain — In this Healio Video Perspective, Jean-François Korobelnik, MD, PhD, discusses the decision of the European Medicines Agency to reject marketing authorization of pegcetacoplan in Europe.
“As it was a second evaluation, the rejection is final. There will be no other appeal possible,” he told Healio at the Euretina congress.
The data for pegcetacoplan (Apellis Pharmaceuticals) for the treatment of geographic atrophy were positive, but not strongly positive, for the overall population of the trials, but post hoc analyses have shown high efficacy in